Memorial Sloan Kettering Cancer Center investigators report that T cell interferon-γ (IFNγ) orchestrates a dendritic-cell–natural-killer-cell circuit that suppresses leptomeningeal metastases in mouse ...

Immunologists from the Institute have been the first to uncover a role for a family of RNA binding proteins in the function ...

As people age, their immune systems become less efficient, posing a challenge for cancer therapies that rely on harnessing immune cells.

I was driving with the window down recently and got a bloodshot eye as a result. It looks terrible, though I’m not in any ...

Researchers have shown that gonadotrophs, cells in the pituitary gland with a key role in puberty and reproduction, come from two different populations, with the majority produced after birth rather ...

Mitochondria turn the food we eat into the energy our cells can use. But when stress hijacks the process they use to maintain ...

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory ...

Recludix Pharma, a leader in the discovery of inhibitors for challenging targets in inflammatory disease, today announced a ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...

Those problems mean that so far only one T-cell engager has reached the market – Amgen’s Blincyto (blinatumomab) for leukaemia – although many others are coming through development.

Here the authors use both patient data and a mouse glomerulonephritis model to show that increased type I interferon may expand a subset of pro-inflammatory T cells for subsequent kidney pathology.